Armata Pharmaceuticals names David House chief financial officer
The company elevated House from senior finance officer to CFO effective July 17, 2026, under a new employment agreement filed with the SEC.
Armata Pharmaceuticals, Inc. disclosed in a Form 8-K that its board of directors named David House as the company's chief financial officer on July 17, 2026, with the appointment taking effect the same day.1 House had held the role of senior vice president, finance, and had been serving as the company's principal financial officer, a position he took on in August 2024.1
In connection with the move, Armata and House signed an employment letter agreement dated July 17, 2026, confirming the terms of his continued employment, under which he reports directly to the company's chief executive officer.1
The agreement sets House's annual base salary at $371,315, with a target annual bonus opportunity of 50% of that base salary, subject to actual performance as determined by the board or its compensation committee.1 The target bonus percentage can be increased, but not decreased, at the board's discretion.1
On the equity side, House is eligible for annual equity awards under the company's 2016 Equity Incentive Plan starting in 2026, with the compensation committee's stated intent to grant an award each year with a grant date fair value of about $300,000, though he is not guaranteed any specific award.1
The agreement also includes severance and change-in-control protections. If Armata terminates House without "Cause" or he resigns for "Good Reason," he would continue receiving his base salary for 12 months, subject to signing a release and complying with restrictive covenants.1 If he is involuntarily terminated within one month before or 12 months after a "Change in Control," his time-based equity awards would vest in full.1
Separately, Armata and Chief Business Officer Pierre Kyme agreed to align the "change in control" definition in Kyme's June 1, 2024 employment agreement with the definition used in House's new agreement.1 Kyme's agreement otherwise remains in effect under its existing terms.1 The filing was signed by CEO Deborah L. Birx, M.D., dated July 18, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.